RecruitingPhase 4

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

United States50 participantsStarted 2026-02-18

Plain-language summary

The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg/Kg/min for at least two hours as part of their standard of care.
✓. Age ≥18 years
✓. Provide written informed consent.

Exclusion criteria

✕. Need for urgent surgery
✕. Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females
✕. Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb/IIIa inhibitor within 48 hours.
✕. Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose

What they're measuring

Optimal platelet reactivity

Timeframe: 2-12 hours

Trial details

NCT IDNCT07225842

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-09

Contact for this trial

Luis Ortega-Paz, MD, PhD

904-244 2060 Luis.Ortega@jax.ufl.edu

View on ClinicalTrials.gov More Coronary Arterial Disease (CAD) trials